STIMNGMHealthcare·Medical Devices#85 in industry

Neuronetics, Inc.

Reports in 8d· 2026-05-05

-25.9% · 90d

$1.66

-0.02 (-1.19%)

News

(1)

April 2026

Apr 6, 20263 weeks ago8-KHealthcare

Neuronetics, Inc. — 8-K Filing

STIMNeuronetics, Inc.

# 🧾 What This Document Is This is an 8-K filing, which companies use to announce major events to investors. This one contains two big announcements: 1. A **consulting agreement** with a recently retired executive. 2. The **departure of the Chief Financial Officer (CFO)**. 👉 **Why it matters:**

Read summaryView on SEC EDGAR

Key Data

Market Cap$115.5M

Open$1.69

Prev Close$1.68

Day Range$1.66 – $1.75

52W Range$0.80 – $4.85

Volume836,419

P/E (TTM)—

EPS$-0.59

Dividend Yield—

Beta0.87

Profit Margin-26.15%

Revenue Growth85.70%

Price Target$4.33(+161.0%)

Next Earnings2026-05-05(8d)

Analyst Ratings

Strong Buy3 analysts

Buy 3Hold 0Sell 0

About

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Healthcare · Medical Devices

658 employees

neurostar.com/neuronetics